Stay updated on Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedPublications section updated to clarify that some publications are provided voluntarily by the study team and that others are auto-filled from PubMed, with a new revision tag v3.3.2. The older wording stating publications are about the study results and that PubMed-derived lists are automatically created by ClinicalTrials.gov (revision v3.2.0) has been removed.SummaryDifference0.2%

- Check33 days agoChange DetectedRemoved a government funding status notice from the page; core trial details and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check47 days agoChange DetectedPublications section with KEYNOTE-010 results has been added, and the study's results dates and IPD sharing details have been updated.SummaryDifference0.4%

- Check76 days agoChange DetectedSummary: The page adds a government-operating-status notice and a v3.2.0 release tag, while removing the v3.1.0 tag. The new notice is the significant change, signaling updated operating status and potential transaction delays.SummaryDifference3%

- Check83 days agoChange DetectedUpgrade from v3.0.2 to v3.1.0: version metadata updated; no substantive content changes detected.SummaryDifference0.1%

- Check98 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Docetaxel in Lung Cancer Clinical Trial page.